Scancell Holdings has secured funding of around £2 million from Innovate UK to initiate a Phase I clinical trial of an experimental SARS-CoV-2 vaccine. Scancell’s DNA vaccines target dendritic cells to stimulate high avidity T cells that identify and destroy diseased cells. This technology has been successfully applied with Scancell’s lead ImmunoBody cancer vaccine, SCIB1, which was safely administered to patients with malignant melanoma in a Phase I/II clinical trial with “outstanding five-year survival,” according to the firm. Source: Pharmatimes 27/08/2020